---
layout: default
title: Ranibizumab
parent: 僅模型預測 (L5)
nav_order: 325
evidence_level: L5
indication_count: 10
---

# Ranibizumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ranibizumab: Repurposing Evaluation — No TxGNN Prediction Available

## One-Sentence Summary

Ranibizumab is an anti-VEGF monoclonal antibody fragment known internationally under the brand name Lucentis, used primarily for ocular neovascular conditions such as wet age-related macular degeneration.
The TxGNN model has **not generated any predicted new indications** for this drug in the current run,
and **no clinical trial or literature evidence** is included in this Evidence Pack.
This report reflects the current data availability and outlines what is needed before evaluation can proceed.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not recorded in this Evidence Pack |
| Predicted New Indication | None — TxGNN output not available |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 (Model prediction only — no actual studies linked) |
| Market Status | Not marketed (0 authorizations on record) |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This Evidence Pack is missing the four core inputs required for a repurposing evaluation — predicted indications, original indication text, mechanism of action, and safety profile. Without these, neither clinical plausibility nor risk assessment can be performed.

**To proceed, the following is needed:**

- **TxGNN prediction output** — `predicted_indications` is currently an empty list; re-run the TxGNN pipeline for DB01270 and verify that the mapping step successfully linked Ranibizumab to disease nodes
- **Original indication data** — `original_indications` is empty; retrieve approved indication text from the DrugBank entry or the package insert
- **Mechanism of action (MOA)** — flagged as a High-severity data gap; query the DrugBank API for DB01270 to obtain the pharmacological mechanism
- **Safety data** — key warnings and contraindications are missing; download and parse the package insert PDF to populate these fields
- **Regulatory status verification** — confirm whether the 0-license result reflects the actual market status or a query coverage limitation
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

